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Jae-Joong Kim, MD,* Suk-Jung Choo, MD,† Cheol-Hyun Chung, MD,† Jae-Won Lee, MD,†
Seong-Wook Park, MD,* Seung-Jung Park, MD*
Seoul, Korea
Objectives This study sought to evaluate the long-term safety and effectiveness of percutaneous coronary intervention (PCI), as
compared with coronary artery bypass grafting (CABG), for unprotected left main coronary artery (LMCA) disease.
Background Data on the long-term (beyond 5-year) comparative results of treatment of unprotected LMCA disease with stent
implantation or CABG are limited.
Methods We performed a 10-year clinical follow-up of 350 patients with unprotected LMCA disease who underwent PCI
with bare-metal stents (BMS) (n  100) or CABG (n  250) from January 1995 to April 1999, and 5-year clinical
follow-up of 395 patients with unprotected LMCA disease who underwent PCI with drug-eluting stents (DES)
(n  176) or CABG (n  219) from January 2003 to May 2004. The primary safety end points were all-cause
mortality and the composite of death, Q-wave myocardial infarction (MI), or stroke, and the primary efficacy end
point was target vessel revascularization (TVR).
Results In the 10-year follow-up cohort of BMS and concurrent CABG, the adjusted risks of death (hazard ratio [HR]: 0.81;
95% confidence interval [CI]: 0.44 to 1.50; p  0.50) and the composite of death, Q-wave MI, or stroke (HR: 0.92;
95% CI: 0.55 to 1.53; p  0.74) were similar between the 2 groups. The rate of TVR was significantly higher in the
group that received BMS (HR: 10.34; 95% CI: 4.61 to 23.18; p  0.001). In the 5-year follow-up cohort of DES and
concurrent CABG, there was no significant difference in the adjusted risk of death (HR: 0.83; 95% CI: 0.34 to 2.07;
p  0.70) or the risk of the composite outcome (HR: 0.91; 95% CI: 0.45 to 1.83; p  0.79). The rates of TVR were
also higher in the DES group than the CABG group (HR: 6.22; 95% CI: 2.26 to 17.14; p  0.001).
Conclusions For the treatment of unprotected LMCA disease, PCI with stent implantation showed similar long-term mortality and
rates of death, Q-wave MI, or stroke. However, stenting, even with DES, was associated with higher rates of repeat
revascularization than was CABG. (J Am Coll Cardiol 2010;56:1366–75) © 2010 by the American College of Cardi-
ology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.097t
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sercutaneous coronary intervention (PCI) for patients with
nprotected left main coronary artery (LMCA) disease
epresents a considerable challenge because of technical
imitations and the risk of acute or late closure attributable
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as partly supported by the Cardiovascular Research Foundation, Seoul, Korea, and a 2o thrombosis or restenosis. Current guidelines and appro-
riateness criteria for coronary revascularization recommend
oronary artery bypass grafting (CABG) as the standard
reatment for patients with LMCA disease (1–3). However,
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October 19, 2010:1366–75 PCI Versus CABG for Left Main Coronary Diseasemprovements in interventional techniques and adjunctive
harmacologic therapy have led to a re-evaluation of the role of
CI as an optional treatment for LMCA disease, and several
tudies have shown the feasibility and the favorable midterm
utcomes of PCI with stenting (4–6). In addition, the avail-
bility of drug-eluting stents (DES), which significantly reduce
he rates of restenosis and repeat revascularization, has widened
he application of PCI to such patients (7–10).
Recently, several reports have shown the successful use of
oronary stenting compared with CABG in patients with
nprotected LMCA disease (11–13). However, there are
urrently no data available on the comparative outcomes
fter PCI or CABG for LMCA disease with follow-up
urations of 5 to 10 years (14). We therefore compared the
ong-term (beyond 5 years) safety and effectiveness of
oronary stenting and CABG among patients with unpro-
ected LMCA disease.
ethods
tudy population and revascularization procedures. The
tudy population consisted of 2 follow-up cohorts: 1) a
0-year follow-up cohort of patients with bare-metal stents
BMS) and concurrent CABG; and 2) a 5-year follow-up
ohort of patients with DES and concurrent CABG, as a
art of the ASAN-MAIN (ASAN medical center–left
AIN revascularization) registry; a single-center, retro-
pective study designed to evaluate the treatment effects of
tenting and CABG for LMCA disease in the “real world.”
For the 10-year follow-up cohort, consecutive patients
ith unprotected LMCA disease (defined as stenosis of
ore than 50%) who underwent PCI with BMS or isolated
ABG at the Asan Medical Center (Seoul, Korea) between
anuary 1, 1995, and April 30, 1999, were included, and the
ollow-up period was extended through May 31, 2009, to
nsure that all patients had an opportunity to provide at
east 10 years of follow-up information. For the 5-year
ollow-up cohort, consecutive patients with unprotected
MCA disease who underwent DES implantation or iso-
ated CABG between January 1, 2003, and May 31, 2004,
ere included, and the follow-up period was extended
hrough June 30, 2009, to ensure that all patients had an
pportunity for at least 5 years of follow-up information if they
ere alive. Patients who had prior CABG, those who under-
ent concomitant valvular or aortic surgery, and those who had
yocardial infarction (MI) with ST-segment elevation or
resented with cardiogenic shock were excluded.
Patients underwent PCI, instead of CABG, because of
ither the patient’s or physician’s preference or the high risk
ssociated with CABG. Methods of stent implantation for
atients with LMCA disease have been described previously
9,15). The choice of the specific type of DES (i.e.,
irolimus-eluting stent [Cypher, Cordis, Johnson & John-
on, Miami Lakes, Florida] or paclitaxel-eluting stent
Taxus, Boston Scientific, Natick, Massachusetts]) was left
o the operator’s discretion. All patients undergoing PCI aere prescribed aspirin plus ticlo-
idine (loading dose, 500 mg) or
lopidogrel (loading dose, 300 or
00 mg) before or during the cor-
nary intervention. After the pro-
edure, aspirin was continued in-
efinitely. Patients treated with
MS were prescribed ticlopidine
250 mg twice a day) for at least
month, and patients treated with
ES were prescribed clopidogrel
75 mg once a day) for at least
months, regardless of DES type
16). Treatment beyond this dura-
ion was at the discretion of the
hysician. Surgical revasculariza-
ion was performed with the use of
tandard bypass techniques (1).
henever possible, the internal
horacic artery was used preferen-
ially for revascularization of the
eft anterior descending artery. Complete revascularization was
erformed when possible using arterial conduits or saphenous
ein grafts.
This study was approved by the local institutional review
oard.
utcome variables and definitions. The primary safety
utcomes were death and the composite of death, Q-wave
I, or stroke. The primary efficacy outcome was target
essel revascularization (TVR).
All deaths were considered cardiac unless an unequivocal
oncardiac cause could be established. The diagnosis of MI
as assessed by the universal definition of MI (17). Q-wave
I was defined as the documentation of a new pathologic
-wave after index treatment. Stroke, as indicated by
eurologic deficits, was confirmed by a neurologist on the
asis of imaging studies. TVR was defined as repeat
evascularization of the treated vessel, including any seg-
ents of the left anterior descending or left circumflex
oronary artery; TLR was defined as any revascularization
erformed on the treated segment. The occurrence of stent
hrombosis in the DES group was assessed by the Academic
esearch Consortium definitions (18).
All events were carefully verified and adjudicated by
ndependent clinicians.
ata collection and follow-up. Clinical, angiographic,
rocedural or operative, and outcome data were recorded in
he dedicated PCI and surgical databases by independent
esearch personnel (16). Clinical follow-up after PCI and
fter CABG was recommended at 1 month, 6 months, and
year and then annually thereafter. Routine angiographic
ollow-up for all patients treated with PCI was recom-
ended 6 to 10 months after the procedure. However,
atients who were at high risk for procedural complications
f angiography and had no symptoms or signs of ischemia,
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
IVUS  intravascular
ultrasound
LMCA  left main coronary
artery
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TLR  target lesion
revascularization
TVR  target vessel
revascularizations well as patients who declined the recommendation, did
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PCI Versus CABG for Left Main Coronary Disease October 19, 2010:1366–75ot undergo routine follow-up angiography. For patients
ho underwent CABG, angiographic follow-up was rec-
mmended only if there were ischemic symptoms or signs
uring follow-up.
For validation of complete follow-up data, information
bout vital status was obtained through May 31, 2009, for
he 10-year follow-up cohort or through June 30, 2009, for
he 5-year follow-up cohort, from the National Population
egistry of the Korea National Statistical Office with the
se of a unique personal identification number. To ensure
ccurate assessment of clinical end points, additional infor-
ation was obtained from visits or telephone contacts with
aseline Characteristics of the Overall Patient PopulationTable 1 Baseline Characteristics of the Overall Patient Populat
Variable
10-Yr Follow-Up Co
BMS
(n  100)
CABG
(n  250) Una
Demographic characteristics
Age, yrs 55.1 10.4 60.7 9.1 
Male sex 60 (60.0) 186 (74.4)
Body mass index, kg/m2 24.6 3.1 24.6 2.7
Cardiac or coexisting conditions
Diabetes mellitus
Any diabetes 21 (21.0) 82 (32.8)
Insulin-requiring 4 (4.0) 18 (7.2)
Hypertension 23 (23.0) 125 (50.0) 
Hyperlipidemia 34 (34.0) 115 (46.0)
Current smoker 36 (36.0) 68 (27.2)
Previous MI 14 (14.0) 40 (16.0)
Previous coronary angioplasty 12 (12.0) 26 (10.4)
Previous congestive heart failure 0 8 (3.2)
Chronic lung disease 0 5 (2.0)
Cerebrovascular disease 4 (4.0) 40 (16.0)
Peripheral vascular disease 4 (4.0) 22 (8.8)
Renal failure 4 (4.0) 13 (5.2)
Ejection fraction (%) 60.3 9.1 56.8 11.9
EuroSCORE value 3.3 2.1 4.4 2.2 
Parsonnet score 3.0 4.0 5.0 4.8 
Clinical indication 
Stable angina 29 (29.0) 27 (10.8)
Unstable angina 68 (68.0) 216 (86.4)
NSTEMI 3 (3.0) 7 (2.8)
Angiographic characteristics
Involved location 
Ostium, midshaft, or both 70 (70.0) 102 (40.8)
Distal bifurcation 30 (30.0) 148 (59.2)
Extent of diseased vessel 
Left main only 55 (55.0) 26 (10.4)
Left main plus single-vessel disease 21 (21.0) 36 (14.4)
Left main plus double-vessel disease 16 (16.0) 56 (22.4)
Left main plus triple-vessel disease 8 (8.0) 132 (52.8)
Right coronary artery disease 18 (18.0) 167 (66.8) 
Total occlusion 1 13 (13.0) 81 (32.4) 
Restenotic lesion NA NA
ata are shown as mean  SD for continuous variables and absolute numbers (percentages) for d
logistic regression model with patient risk factors and propensity score as independent control
BMS  bare-metal stent(s); CABG  coronary-artery bypass grafting; DES  drug-eluting stent(s); MI
nfarction.iving patients or family members and from medical records
btained from other hospitals, as necessary.
tatistical analysis. Continuous variables were compared
ith the t test or Wilcoxon rank sum tests, and categorical
ariables were compared with the chi-square statistics or
isher exact test, as appropriate. Survival curves were
onstructed using Kaplan-Meier estimates and compared
ith the log-rank test.
To compensate for the nonrandomized design of our
bservational study and to test for selection bias, we used
ropensity-score methods (19). The propensity scores were
stimated without regard to outcomes, using multiple logis-
5-Yr Follow-Up Cohort
p Value
DES
(n  176)
CABG
(n  219)
p Value
d Adjusted* Unadjusted Adjusted*
0.47 61.1 11.5 62.4 8.1 0.20 0.84
0.86 125 (71.0) 162 (74.0) 0.51 0.83
0.82 24.5 2.6 24.6 2.9 0.58 0.99
0.57 52 (29.5) 81 (37.0) 0.12 0.61
0.88 8 (4.5) 12 (5.5) 0.67 0.25
0.95 83 (47.2) 121 (55.3) 0.11 0.66
0.63 62 (35.2) 121 (55.3) 0.001 0.98
0.79 31 (17.6) 43 (19.6) 0.61 0.92
0.81 15 (8.5) 24 (11.0) 0.42 0.81
0.98 41 (23.3) 31 (14.2) 0.02 0.90
—† 1 (0.6) 11 (5.0) 0.01 0.72
—† 4 (2.3) 8 (3.7) 0.43 0.79
0.99 15 (8.5) 26 (11.9) 0.28 0.80
0.63 3 (1.7) 26 (11.9) 0.001 0.91
0.99 10 (5.7) 15 (6.8) 0.64 0.86
0.46 59.9 7.7 56.5 11.2 0.001 0.62
0.90 3.3 2.7 4.5 2.6 0.001 0.92
0.75 5.4 4.7 5.8 6.6 0.001 0.93
0.98 0.001 0.96
97 (55.1) 36 (16.4)
61 (34.7) 171 (78.1)
18 (10.2) 12 (5.5)
0.40 0.78 0.96
57 (32.4) 68 (31.1)
119 (67.6) 151 (68.9)
0.99 0.001 0.98
40 (22.7) 10 (4.6)
46 (26.1) 13 (5.9)
47 (26.7) 56 (25.6)
43 (24.4) 140 (63.9)
0.86 74 (42.0) 176 (80.4) 0.001 0.91
0.59 NA NA NA NA
NA 9 (5.1) 5 (2.3) 0.13 0.94
ous variables. *Propensity score-adjusted p value. Comparisons were performed with the use of
s. †Could not be estimated.ion
hort
djuste
0.001
0.008
0.86
0.03
0.27
0.001
0.04
0.10
0.64
0.66
0.11
0.33
0.002
0.12
0.79
0.004
0.001
0.001
0.001
0.001
0.001
0.001
0.001
NA
ichotom
variable myocardial infarction; NA  not available; NSTEMI  non–ST-segment elevation myocardial
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October 19, 2010:1366–75 PCI Versus CABG for Left Main Coronary Diseaseic regression analysis. A full nonparsimonious model was
eveloped that included all variables shown in Table 1.
odel discrimination was assessed with c-statistics, and
odel calibration was assessed with Hosmer-Lemeshow
tatistics. The individual propensity score, as well as the type
f revascularization, was incorporated into the Cox regres-
ion model as a covariate to calculate the propensity-
djusted hazard ratio (HR). The propensity score was also
ubdivided into quartiles (20). Treatment effect was sepa-
ately estimated within each quartile, and quartile estimates
ere combined to measure an overall estimate of the
reatment effect. All statistical analyses were performed
sing SAS version 9.1 (SAS Institute, Cary, North Caro-
ina). A 2-tailed p value of 0.05 was considered statisti-
ally significant.
esults
aseline characteristics and revascularization procedures.
etween January 1995 and April 1999, a total of 350
atients with unprotected LMCA disease met the criteria
or inclusion. Of these, 100 were treated with PCI with
MS and 250 with CABG, and were eligible for the
0-year follow-up cohort. Between January 2003 and May
004, a total of 395 patients with unprotected LMCA
isease met the study inclusion criteria and met none of the
riteria for exclusion. Of these, 176 who were treated with
CI with DES and 219 with CABG were eligible for the
-year follow-up cohort.
The baseline characteristics of study patients according
o revascularization procedure are shown in Table 1.
ABG patients had a significantly higher-risk clinical
nd angiographic profile than PCI patients. Procedural
haracteristics are presented in Table 2. For the 10-year
ollow-up cohort, complete revascularization was achieved in
7 BMS patients (67.0%) and in 209 CABG patients (83.6%;
 0.001). For the 5-year follow-up cohort, complete revas-
ularization was achieved in 126 DES patients (71.6%) and in
76 CABG patients (80.4%; p  0.04). In the DES group,
irolimus-eluting stents were used exclusively, and intravascular
ltrasound (IVUS)-guided stenting was performed in almost
0% of patients.
bserved in-hospital and long-term event rates. The
bserved (unadjusted) in-hospital clinical events are
hown in Table 3. Individual rates of in-hospital death,
I, stroke, and TVR were not different between the 2
roups. However, the rate of the composite of death,
-wave MI, or stroke in the CABG group was signifi-
antly higher than in the stenting group, irrespective of
tent type.
For the 10-year follow-up cohort, complete follow-up
ata for major clinical events at 10 years were obtained in
6.9% of the overall cohort (96.0% for the BMS group and
7.2% for the CABG cohort). For the 5-year follow-up
ohort, complete follow-up data for major clinical events at
years after index treatment were obtained in 97.2% of the sverall cohort (97.7% for the DES group and 96.8% for the
ABG group). Crude event rates and unadjusted long-term
vent-free survival curves according to treatment approach
re presented in Table 3 and Figure 1. The observed
unadjusted) long-term rates of death and the composite of
eath, Q-wave MI, or stroke were significantly lower in the
CI group than in the CABG group, whereas the rate of
VR was higher in the PCI group.
In the DES group, 3 patients had definite thrombosis,
one had probable thrombosis, and 2 had possible throm-
osis. At 5-year follow-up, the cumulative incidence of
efinite or probable stent thrombosis was 1.8%. Among
atients with definite or probable stent thrombosis, 1
atient had acute, 1 had subacute, and 1 had very late (4.3
ears after the procedure) thrombosis. Acute and subacute
ases were on dual antiplatelet therapy at the time of
hrombotic events, and a very late case arose 2 months later,
fter all antiplatelet therapy was interrupted.
djusted primary safety and efficacy outcomes. Table 4
nd Figure 2 represent the adjusted primary safety and
fficacy outcomes based on revascularization procedure. The
-statistic for the propensity score model was 0.87 (Hosmer-
emeshow goodness-of-fit p  0.56) in the 10-year cohort
nd 0.88 (Hosmer-Lemeshow goodness-of-fit p  0.97) in
he 5-year cohort. All covariates differed nonsignificantly
fter propensity score adjustment (Table 1). In the propen-
rocedural Characteristics of Patients Treated WithABG and StentingTable 2 Procedu al Characteristics of Patients Treated WithCABG and Stenting
10-Yr Follow-Up
Cohort
5-Yr Follow-Up
Cohort
CABG patients, n 250 219
On-pump surgery 243 (97.2) 178 (81.3)
Grafts per patients 4.3 1.2 3.3 1.0
Arterial grafts per patient 1.1 0.7 2.5 0.9
Venous grafts per patient 3.2 1.4 0.9 0.7
Use of at least 1 arterial conduit 226 (90.4) 215 (98.2)
Use of IMA-to-LAD graft 225 (90.0) 209 (95.4)
PCI patients, n 100 with BMS 176 with DES
Stent type
Sirolimus-eluting stents — 168 (95.5)
Paclitaxel-eluting stents — 8 (4.5)
Total number of stents in LMCA lesions 1.3 0.6 1.3 0.6
Total length of stents in LMCA lesions 16.2 9.2 35.2 27.0
Total number of stents in a patient 1.6 0.9 2.5 1.4
Maximal balloon size 4.4 0.6 3.9 0.5
Maximal pressure, atm 15.8 2.4 18.7 2.4
Support of intra-aortic balloon pump 5 (5.0) 12 (6.8)
Guidance of intravascular ultrasound 67 (67.0) 157 (89.2)
Use of glycoprotein IIb/IIIa inhibitor 5 (5.0) 11 (6.3)
Distal bifurcation treatment, n 30 119
Single stenting 15 (50.0) 71 (59.7)
Complex bifurcation stenting 15 (50.0) 48 (40.3)
ata are shown asmean SD for continuous variables and absolute numbers (%) for dichotomous
ariables.
IMA  internal mammary artery; LAD  left anterior descending coronary artery; LMCA  left
ain coronary artery; PCI percutaneous coronary intervention; other abbreviations as in Table 1.ity score– and propensity score quartile–adjusted analyses,
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PCI Versus CABG for Left Main Coronary Disease October 19, 2010:1366–75ong-term risks of death and the composite of death,
-wave MI, or stroke in the 10-year follow-up cohort of
MS and concurrent CABG were similar in the 2 groups.
owever, the adjusted risk of TVR was significantly higher
n the PCI group. These findings were consistent with those
f the 5-year follow-up cohort of DES and concurrent
ABG.
iscussion
n a long-term (10-year for BMS and 5-year for DES)
bservational study of consecutive patients with unprotected
MCA disease, we found that the adjusted long-term risks
f death and a composite of serious outcomes (death,
-wave MI, or stroke) were similar in the PCI group and
he CABG group. In contrast, the rate of TVR was
ignificantly lower in the CABG group than in the PCI
roup.
Several small observational studies comparing DES and
ABG in LMCA disease showed that the early clinical
n-Hospital and Long-Term Clinical Events According to Study GrouTable 3 In-Hospital and Long-Term Clinical Events According to
10-Yr Follow-Up Cohort
BMS (n  100) CABG (n  250)
Clinical events, n (%)
In-hospital outcomes
Death 0 6 (2.4)
Cardiac 0 4 (1.6)
Noncardiac 0 2 (0.8)
MI 8 (8.0) 21 (8.4)
Q-wave 2 (2.0) 14 (5.6)
Non–Q-wave 6 (6.0) 7 (2.8)
Stroke 0 2 (0.8)
Death, Q-wave MI, or stroke 2 (2.0) 19 (7.6)
Any revascularization 2 (2.0) 1 (0.4)
Percutaneous 1 (1.0) 1 (0.4)
Surgical 1 (1.0) 0
TLR 2 (2.0) 1 (0.4)
TVR 2 (2.0) 1 (0.4)
Cumulative long-term outcomes
Death 15 (15.9) 59 (24.1)
Cardiac 6 (6.9) 25 (11.0)
Noncardiac 9 (9.6) 34 (14.8)
MI 15 (16.0) 29 (12.1)
Q-wave 7 (7.8) 20 (8.5)
Non–Q-wave 8 (8.3) 9 (3.6)
Stroke 5 (5.5) 18 (8.8)
Death, Q-wave MI, or stroke 24 (25.2) 78 (32.1)
Any revascularization 41 (43.1) 15 (6.7)
Percutaneous 31 (34.2) 14 (6.2)
Surgical 10 (10.2) 1 (0.5)
TLR 24 (24.9) 11 (4.9)
TVR 35 (36.7) 11 (4.9)
alues are n (%). *Outcome rates were derived from Kaplan-Meier curves. †The p values were calcu
he log-rank test for cumulative long-term outcomes.
TLR  target lesion revascularization; TVR  target vessel revascularization; other abbreviationvents of left main stenting were similar or superior to those cf bypass surgery, because of a significant increase in
eriprocedural MI or stroke in CABG patients, and that
id-term mortality within 1 year was similar in the PCI and
ABG groups (11,12,21,22). However, the risk of TVR
as consistently higher with PCI than with CABG. Recent
esults from the MAIN-COMPARE (Revascularization for
nprotected Left Main Coronary Artery Stenosis: Com-
arison of Percutaneous Coronary Angioplasty Versus Sur-
ical Revascularization) registry with median 3-year
ollow-up and the LMCA subgroup analysis of the
YNTAX (Synergy Between Percutaneous Coronary Inter-
ention With TAXUS and Cardiac Surgery) trial also
howed similar findings (13,23). On the basis of these
esults, recent practice guidelines have updated the class of
ecommendation of PCI for patients with unprotected
MCA disease from class III to IIb (2). However, several
linical trials comparing PCI to CABG for multivessel
isease, in which LMCA disease was mostly excluded,
requently include patients with follow-up durations of 5 to
0 years (24,25). Whether or not the results achieved with
y Group*
5-Yr Follow-Up Cohort
p Value† DES (n  176) CABG (n  219) p Value†
0.19 0 5 (2.3) 0.07
0.58 0 5 (2.3) 0.07
0.99 0 0 —
0.90 19 (10.8) 17 (7.8) 0.30
0.26 3 (1.7) 8 (3.7) 0.36
0.21 16 (9.1) 9 (4.1) 0.04
0.99 1 (0.6) 6 (2.7) 0.14
0.046 4 (2.3) 18 (8.2) 0.01
0.20 1 (0.6) 1 (0.5) 0.99
0.49 1 (0.6) 1 (0.5) 0.99
0.29 0 0 —
0.20 1 (0.6) 1 (0.5) 0.99
0.20 1 (0.6) 1 (0.5) 0.99
0.02 10 (5.9) 24 (11.2) 0.03
0.10 6 (3.7) 13 (6.1) 0.22
0.08 4 (2.3) 11 (5.4) 0.06
0.43 27 (15.7) 21 (9.7) 0.12
0.72 9 (5.5) 12 (5.6) 0.67
0.09 18 (10.2) 9 (4.1) 0.02
0.22 3 (1.7) 12 (5.9) 0.04
0.04 17 (10.0) 41 (19.1) 0.004
0.001 32 (19.7) 10 (5.0) 0.001
0.001 27 (16.6) 9 (4.5) 0.002
0.001 5 (3.1) 1 (0.5) 0.11
0.001 21 (13.2) 6 (2.9) 0.001
0.001 26 (16.2) 6 (2.9) 0.001
ith the use of the chi-square test or Fisher exact test for in-hospital outcomes, as appropriate, and
Table 1.p*Stud
lated woronary stents will be stable for 5 to 10 years remains to be
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ur knowledge, this study is the longest follow-up study to
ompare coronary stenting, even with BMS or DES, with
ypass surgery for treatment of unprotected LMCA steno-
is. Therefore, our study provides important information
bout a sufficient long-term effect of stenting as compared
Figure 1 Unadjusted Survival Curves
(A and B) show long-term survival, (C and D) show survival free from Q-wave myoc
larization. A, C, and D show 10-year unadjusted survival curves between bare-met
show 5-year unadjusted survival curves between drug-eluting stents (DES) and conith CABG, and it is probably best viewed as an indication Po proceed with larger, randomized trials with long-term
ollow-up.
The current study extends the previous findings of
everal observational studies and clinical trials up to 5 to
0 years. Although adjusted risks of safety outcomes were
imilar between the 2 groups, the benefits of surgery over
infarction or stroke, and (E and F) show survival free from target vessel revascu-
ts (BMS) and concurrent coronary artery bypass grafting (CABG), and B, D, and F
t CABG.ardial
al sten
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antly higher rate of follow-up angiography in the PCI
roup than in the CABG group (94.0% in BMS vs.
9.6% in concurrent CABG, p  0.001, and 76.1% in
ES vs. 11.9% in concurrent CABG, p  0.001) could
ave penalized the PCI group, and the rate of asymp-
omatic graft occlusion might have been underestimated
n the CABG group. In addition, higher rates of in-
omplete revascularization in PCI patients might have
nfluenced the rate of subsequent late revascularization,
articularly if those were scheduled for surveillance an-
iography. The increase in the rate of repeat revascular-
zation with PCI did not appear to translate into signif-
cant overall increases of mortality or serious safety
utcomes. The risk of repeat revascularization after PCI
eeds to be balanced against the greater invasiveness and
he higher procedural risk associated with CABG, with-
ut significant differences in long-term safety outcomes.
In our multicenter, observational study (MAIN-
OMPARE registry), there was a trend toward higher rates
f death and the composite end point (death, Q-wave MI,
r stroke) in the DES group compared with CABG (13).
owever, a nonsignificant trend toward higher event rates
ith DES was not seen in this longer-term follow-up study.
ecause current available studies were underpowered to
etect significant differences in mortality or hard end points,
hese findings should be confirmed or refuted through a
arger cohort of patients with longer-term follow-up.
Recently, long-term safety concerns about DES use have
azard Ratios for Primary Safety and Efficacy Clinical Outcomes AfTable 4 Hazard Ratios for Primary Safety and Efficacy Clinical
Model
Death
Hazard Ratio
(95% CI) p
10-yr follow-up cohort (BMS vs. concurrent CABG)
Crude 0.53 (0.31–0.90)
Propensity score adjusted 0.81 (0.44–1.50)
Stratified analyses based on propensity scores
Quartile 1 2.35 (0.32–17.46)
Quartile 2 0.67 (0.20–2.20)
Quartile 3 0.49 (0.14–1.71)
Quartile 4 2.41 (0.52–11.03)
Summary‡ 0.91 (0.49–1.69)
5-yr follow-up cohort (DES vs. concurrent CABG)
Crude 0.46 (0.22–0.94)
Propensity score adjusted 0.83 (0.34–2.07)
Stratified analyses based on propensity scores
Quartile 1 —†
Quartile 2 0.63 (0.07–5.41)
Quartile 3 0.56 (0.16–1.94)
Quartile 4 —†
Summary‡ 0.58 (0.23–1.46)
Hazard ratios are for the stent group as compared with the CABG group. †Could not be estimate
or composite of death, Q-wave MI, or stroke; p  0.67 for TVR) and in the 5-year follow-up cohor
CI  confidence interval; other abbreviations as in Tables 1 and 3.een raised, due to increased risks of late stent thrombosis cnd late mortality (26,27). Considering the catastrophic
onsequences of stent thrombosis in LMCA stenting, a lack
f long-term clinical data have hampered the widespread
se of PCI with DES as an alternative to CABG for such
atients. Overall ST rates (definite or probable) in patients
ith unprotected LMCA stents have been reported to range
etween 1% and 2% within 1 to 3 years (13,28–30).
lthough our number of patients was too small to accurately
ssess the long-term risk of stent thrombosis, we observed a
imilar incidence of definite or probable stent thrombosis
1.8%), providing further evidence that LMCA stenting
ith DES results in lower or, at worst, similar rates of stent
hrombosis and long-term mortality than are observed in
atients with other coronary lesions (31).
In our study, the adjunctive use of IVUS is generally
ecommended while performing left main stenting. Al-
hough the clinical impact of IVUS in DES placement is
ot yet clear, routine use of IVUS can be very helpful in
ptimally expanding the stent, with or without post-stent
alloon dilation, to avoid under- or overstretch of the stent
iameter in complex settings such as left main disease, and
ight partly contribute to better long-term outcomes as
ompared with conventional angiography guidance (32).
tudy limitations. First, our study is an observational
tudy, and therefore, the choice of treatment was at the
iscretion of the physician or the patient. Although we
sed propensity analysis to enable a rigorous adjustment
or selection bias and confounding, there is no way to
liminate bias caused by the influence of unmeasured
tenting as Compared With After CABG*mes After Stenting as Compared With After CABG*
Composite of Death,
Q-Wave MI, or Stroke TVR
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
0.64 (0.42–0.99) 0.04 8.80 (4.57–16.91) 0.001
0.92 (0.55–1.53) 0.74 10.34 (4.61–23.18) 0.001
1.78 (0.24–13.09) 0.57 —† —†
0.73 (0.26–2.04) 0.54 5.07 (1.21–21.25) 0.03
0.78 (0.33–1.86) 0.58 18.80 (4.23–83.46) 0.001
2.27 (0.65–7.91) 0.20 9.71 (1.30–72.37) 0.03
1.02 (0.61–1.71) 0.93 9.25 (4.17–20.50) 0.001
0.45 (0.26–0.78) 0.005 4.64 (2.01–10.68) 0.001
0.91 (0.45–1.83) 0.79 6.22 (2.26–17.14) 0.001
0.55 (0.07–4.04) 0.55 15.44 (2.17–110.09) 0.006
0.78 (0.22–2.75) 0.69 2.35 (0.53–10.52) 0.26
0.69 (0.23–2.04) 0.50 6.00 (0.77–46.89) 0.09
—† —† —† —†
0.79 (0.39–1.59) 0.50 5.31 (1.91–14.71) 0.001
elihood ratio test for homogeneity: in the 10-year follow-up cohort (p  0.30 for death; p  0.45
.99 for death; p  0.99 for composite of death, Q-wave MI, or stroke; p  0.52 for TVR).ter SOutco
Value
0.02
0.50
0.40
0.51
0.26
0.26
0.76
0.04
0.70
—†
0.68
0.36
—†
0.25
d. ‡Likonfounders, or the presence of patients deemed to be
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ubgroup analysis, LMCA-specific randomized trials
ith a larger number of patients and longer follow-up,
uch as the PRE-COMBAT (Randomized Comparison
f Bypass Surgery Versus Angioplasty Using Sirolimus-
luting Stent in Patients With Left Main Coronary
rtery Disease) or EXCEL (Evaluation of Xience Prime
Figure 2 Adjusted Survival Curves
(A and B) show long-term survival, (C and D) show survival free from Q-wave myoc
revascularization (TVR). A, C, and D show 10-year adjusted survival curves betwee
B, D, and F show 5-year adjusted survival curves between drug-eluting stents (DES
model at the mean level of the propensity score.ersus Coronary Artery Bypass Surgery for Effectiveness nf Left Main Revascularization) clinical trial, are needed
o confirm whether PCI treatment for LMCA disease is
quivalent to CABG (14). Second, our analysis was
nderpowered to detect significant differences in mortal-
ty and serious composite outcomes among the treatment
roups and to assess the long-term risk of stent throm-
osis, due to the limited number of events. Third, we did
infarction (MI) or stroke, and (E and F) show survival free from target vessel
-metal stents (BMS) and concurrent coronary artery bypass grafting (CABG), and
concurrent CABG. The curves represent estimations from the Cox regressionardial
n bare
) andot use a detailed scoring system (i.e., the SYNTAX
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PCI Versus CABG for Left Main Coronary Disease October 19, 2010:1366–75core) to more accurately reflect atherosclerotic disease
urden and anatomic complexity. Fourth, the average
urgical risk of our study population, as measured by
uroSCORE and Parsonnet score, was relatively low.
inally, the particulars of clinical practice as well as the
pecific expertise of the interventional cardiologists and
ardiac surgeons in our institution may differ from those
f other institutions and practitioners, potentially limit-
ng the reproducibility of these results in other settings.
onclusions
uring 10-year follow-up with BMS and 5-year follow-up
ith DES, PCI with coronary stenting and CABG were
ssociated with similar long-term rates of death and the
omposite end point of death, Q-wave MI, or stroke for
atients with unprotected LMCA disease. Rates of TVR
ere higher among patients who underwent PCI than
mong those who underwent CABG. These findings
hould be confirmed or refuted through larger clinical trials
ith long-term follow-up.
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